Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study
Daniel Mrak, Elisabeth Simader, Daniela Sieghart, Péter Mandl, Helga Radner, Thomas Perkmann, Helmuth Haslacher, Margareta Mayer, Maximilian Koblischke, Philipp Hofer, Lisa Göschl, Felix Kartnig, Thomas Deimel, Andreas Kerschbaumer, Thomas Hummel, Barbara Kornek, Renate Thalhammer, Karin Stiasny, Stefan Winkler, Josef S Smolen, Judith H. Aberle, Daniel Aletaha, Leonhard X. Heinz, Michael Bonelli
Topics & Concepts
MedicineImmunogenicityCoronavirus disease 2019 (COVID-19)RituximabVaccination2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyImmunologyOpen labelAntibodyAdverse effectInternal medicineOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesHeparin-Induced Thrombocytopenia and Thrombosis